Drug application
SUPRENZA (PHENTERMINE HYDROCHLORIDE)
Drugs@FDA NDA 202088 · CITIUS PHARMS
Key facts
| Drug name | SUPRENZA |
|---|---|
| Active ingredients | PHENTERMINE HYDROCHLORIDE |
| Application type | NDA |
| Application number | 202088 |
| Company | CITIUS PHARMS |
| Dosage forms | TABLET, ORALLY DISINTEGRATING, ORAL |
| Strength | 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Efficacy |
| Latest submission status date | Mar 27, 2012 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: